Published in Med Oncol on April 10, 2014
Engineering large animal models of human disease. J Pathol (2015) 0.94
Involvement of IL17A, IL17F and IL23R Polymorphisms in Colorectal Cancer Therapy. PLoS One (2015) 0.76
NOD2 mutations and colorectal cancer - Where do we stand? World J Gastrointest Surg (2016) 0.76
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
[Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme]. Ann Pathol (2011) 1.44
Ancient local evolution of African mtDNA haplogroups in Tunisian Berber populations. Hum Biol (2010) 1.44
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res (2005) 1.25
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A (2002) 1.23
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
Spectrum of PTCH1 mutations in French patients with Gorlin syndrome. J Invest Dermatol (2003) 1.16
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Werner syndrome and mutations of the WRN and LMNA genes in France. Hum Mutat (2006) 1.07
Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer (2003) 1.06
DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res (2008) 1.06
Molecular insights on basal-like breast cancer. Breast Cancer Res Treat (2012) 1.05
Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. Int J Med Sci (2012) 1.04
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon. Hered Cancer Clin Pract (2012) 1.00
BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci (2008) 1.00
Mitochondrial DNA structure in North Africa reveals a genetic discontinuity in the Nile Valley. Am J Phys Anthropol (2011) 0.98
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol (2002) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. J Mol Diagn (2012) 0.97
CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res (2011) 0.97
BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol (2012) 0.97
Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo (2010) 0.96
Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics (2014) 0.95
Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep (2011) 0.95
Central adiposity as a major risk factor of ovarian cancer. Anticancer Res (2009) 0.93
Epigenetic modifications in prostate cancer. Epigenomics (2014) 0.93
Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia. Pathol Oncol Res (2011) 0.92
Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo (2009) 0.91
Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer (2011) 0.91
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. Int J Cancer (2005) 0.91
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat (2010) 0.91
Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families. Oncogene (2002) 0.89
Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res (2009) 0.89
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One (2011) 0.88
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines. Br J Nutr (2002) 0.87
The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer (2011) 0.87
Genetic susceptibility to type 2 diabetes: a global meta-analysis studying the genetic differences in Tunisian populations. Hum Biol (2012) 0.87
Gene expression profiling of breast cancer cell lines in response to soy isoflavones using a pangenomic microarray approach. OMICS (2010) 0.87
miRNAs differentially expressed in prostate cancer cell lines after soy treatment. In Vivo (2011) 0.86
DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol Cancer (2008) 0.86
Testicular synovial sarcoma: a case report. Cancer Biol Med (2012) 0.86
Evaluation of breast cancer risk in a multigenic model including low penetrance genes involved in xenobiotic and estrogen metabolisms. Nutr Cancer (2010) 0.86
Concern Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol (2012) 0.86
DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics (2011) 0.86
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev (2005) 0.86
Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor suppressor genes in mammary glands of female Wistar rats. Cancer Res (2003) 0.85
Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo (2009) 0.85
Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Clin Chim Acta (2011) 0.85
Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast cancer in Tunisian patients. Cancer Invest (2010) 0.85
Methylenetetrahydrofolate reductase and methionine synthase polymorphisms and risk of bladder cancer in a Tunisian population. Cancer Genet Cytogenet (2007) 0.84
Association of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene with type 2 diabetes in two ethnic groups of Jerba Island in Tunisia. J Renin Angiotensin Aldosterone Syst (2009) 0.84
Effects of the phytoestrogens genistein and daidzein on BRCA2 tumor suppressor gene expression in breast cell lines. Nutr Cancer (2003) 0.84
NY-ESO-1 expression and immunogenicity in prostate cancer patients. Tunis Med (2011) 0.84
Immunohistochemical expression of RARalpha, RARbeta, and Cx43 in breast tumor cell lines after treatment with lycopene and correlation with RT-QPCR. J Histochem Cytochem (2007) 0.83
Genetic structure of Tunisian ethnic groups revealed by paternal lineages. Am J Phys Anthropol (2011) 0.83
HLA class II susceptibility to cervical cancer among Tunisian women. Bull Cancer (2012) 0.83
Breast cancer cell response to genistein is conditioned by BRCA1 mutations. Biochem Biophys Res Commun (2009) 0.83
Positive link between variant Toll-like receptor 4 (Asp299Gly and Thr399Ile) and colorectal cancer patients with advanced stage and lymph node metastasis. Tumour Biol (2013) 0.83
Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol (2014) 0.82
Polymorphisms in one-carbon metabolism pathway genes and risk for bladder cancer in a Tunisian population. Cancer Genet Cytogenet (2009) 0.82
Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin Chim Acta (2004) 0.82
BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection. Oncol Rep (2011) 0.82
Genistein and daidzein: different molecular effects on prostate cancer. Anticancer Res (2013) 0.82
Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing. Fam Cancer (2015) 0.82
Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics (2013) 0.82